Study S000259

Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol, Statistical Analysis Plan, and Informed Consent Form (PDF)

Registration

Registration: NCT02014740
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 100
Start: 2014-03
Primary completion: 2017-03
Lead sponsor: University of Miami
Conditions: Type 2 Diabetes; Overweight; Obesity
Interventions: DRUG:Liraglutide; DRUG:Metformin
Results posted: TRUE

Registered primary outcomes

Echocardiographic Epicardial Fat Thickness [6 months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025431	Liraglutide causes large and rapid epicardial fat reduction. Iacobellis G, Obesity (Silver Spring, Md.)	2017	Randomized trial	PMID 28124506 DOI	cites ClinicalTrials.gov:NCT02014740; registry reference DERIVED:28124506